Divestiture, Agreement, Acquisition, Home Health Assessment, and Quarterly Report - Research Report on Osiris, Clovis, PDL,

  Divestiture, Agreement, Acquisition, Home Health Assessment, and Quarterly
    Report - Research Report on Osiris, Clovis, PDL, Amedisys, and Acadia
                                  Healthcare

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, October 24, 2013

NEW YORK, October 24, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Osiris
Therapeutics, Inc. (NASDAQ: OSIR), Clovis Oncology, Inc. (NASDAQ: CLVS), PDL
BioPharma, Inc. (NASDAQ: PDLI), Amedisys Inc. (NASDAQ: AMED), and Acadia
Healthcare Company, Inc. (NASDAQ: ACHC). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Osiris Therapeutics, Inc. Research Report

On October 10, 2013, Osiris Therapeutics, Inc. (Osiris) announced that it has
entered into an agreement with a wholly-owned subsidiary of Mesoblast Limited
for the sale of its culture-expanded mesenchymal stem cell (ceMSC) business,
including Prochymal. According to Osiris, the transaction is worth up to $100
million in initial consideration and milestone payments, with additional
royalty payments on sales of Prochymal and other products utilizing the
acquired ceMSC technology. Peter Friedli, Chairman of Osiris, stated, "With
this transaction, we will focus our business on those areas that are of
greatest commercial value to Osiris moving forward." Friedli continued,
"Furthermore, we have substantially strengthened our balance sheet, reduced
R&D expense and preserved future value from Prochymal through a series of
milestone and royalty payments." The Company further reported that it expects
to record the closing and asset transfer consideration of $51 million in Q4 FY
2013. The Full Research Report on Osiris Therapeutics, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/82ba_OSIR]

--

Clovis Oncology, Inc. Research Report

On October 21, 2013, Clovis Oncology, Inc. (Clovis) announced that it has
signed an agreement with QIAGEN for the development of a companion diagnostic
test to identify the T790M resistance mutation in patients with epidermal
growth factor receptor (EGFR) driven non-small cell lung cancer (NSCLC) for
CO-1686. Clovis reported that the Companies have also signed a non-exclusive
Master Collaboration Agreement which will enable additional Clovis assets
requiring supporting companion diagnostic assays to be rapidly developed using
QIAGEN sample and assay technologies where appropriate. The Full Research
Report on Clovis Oncology, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/6a2a_CLVS]

--

PDL BioPharma, Inc. Research Report

On October 21, 2013, PDL BioPharma, Inc. (PDL) announced that it has acquired
the rights to receive royalties and milestones payable on sales of Type 2
diabetes products licensed by Depomed, in exchange for a $240.5 million cash
payment. PDL reported that it will receive all royalty and milestone payments
due under the agreements until it has received payments equal to two times the
cash payment made to Depomed, after which all the payments received will be
shared evenly between PDL and Depomed. According to the Company, it has also
acquired certain rights to royalties and milestones on Depomed's Acuform,
which is currently in development by Boehringer Ingelheim and Janssen
Pharmaceutica. The Full Research Report on PDL BioPharma, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/066b_PDLI]

--

Amedisys Inc. Research Report

On October 4, 2013, Amedisys Inc. (Amedisys) announced that Michael Fleming,
MD, FAAFP and Chief Medical Officer for Amedisys, responded to the recent
Journal of the American Medical Association (JAMA) article, "The Future of the
Medicare Home Health Program," authored by Steven Landers, MD. Fleming stated,
"I applaud Dr. Landers, not only for his assessment that the Affordable Care
Act offers opportunities for improving the value of home healthcare, but that
further reforms are necessary to ensure that older Americans get the home
support they need and Medicare gets value." He continued, "The value of home
healthcare is little recognized and largely misunderstood. Many have
overlooked the advantages it represents for millions of Americans, especially
the elderly, chronically ill population. I believe the leaders in our
industry, Amedisys included, must begin to support objective research into the
program's efficacy and areas for improvement. Only then will we be able to
prove the value of the skilled care we provide in the home each day." The Full
Research Report on Amedisys Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/56b5_AMED]

--

Acadia Healthcare Company, Inc. Research Report

On October 15, 2013, Acadia Healthcare Company, Inc. (Acadia Healthcare)
announced that it will release its Q3 2013 earnings results after the market
close on Tuesday, October 29, 2013. Acadia reported that the Q3 2013
conference call will be held on Wednesday, October 30, 2013 at 9:00 a.m. ET.
The Company further informed that interested parties may access the live
broadcast through the Investors section on its website, wherein a replay will
also be available until November 12, 2013. The Full Research Report on Acadia
Healthcare Company, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/c556_ACHC]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)